Artimmune
- Company typePrivate
- Founded2009
- HeadquartersOrléans, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
Artimmune firmographics
Firmographics- Name
- Artimmune
- Legal name
- Artimmune
- Website
- https://artimmune.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Artimmune industry classification
Industry- Product category
- Preclinical Contract Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Artimmune is headquartered
LocationHeadquarters
- HQ city
- Orléans
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Artimmune business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services (CRO): Fee-for-service preclinical research contracts providing consulting, study design, execution, and reporting for immunology and inflammation drug discovery programs. Revenue generated through project-based contracts with pharma and biotech clients.
- Consulting Services: Expert scientific consulting in immunology, inflammation, and lung diseases for drug discovery programs.
- Subcontracting Services: Specialized subcontracting services for preclinical studies requiring specific expertise in immunology and respiratory disease models.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Artimmune product offering
Product offeringCore offering
Artimmune is a French contract research organization (CRO) that offers consulting, preclinical research, and subcontracting services in immunology and inflammation, with an emphasis on lung diseases. The company provides in vivo and in vitro preclinical studies, validated respiratory disease models, biomarker strategies, and analytical services to pharmaceutical and biotechnology clients advancing drug discovery programs.
Product overview
Artimmune is a preclinical Contract Research Organization (CRO) offering a unified portfolio of drug discovery services for inflammation and infection, with particular expertise in immunology and lung diseases. The core offering comprises In Vivo Services (preclinical disease models and functional assessments including plethysmography, bronchoalveolar lavage, histology, and immunohistochemistry) and In Vitro Services (primary cell assays, cytokine profiling, and flow cytometry). These services are supported by a Technology Platform with validated respiratory models and analytics, and a Preclinical Equipments portfolio. The company operates as a single integrated service provider rather than a modular software platform, delivering end-to-end preclinical research from model development through biomarker analysis.
Differentiator
Problem solved
Functional benefit
Products and services
- In Vivo Services Preclinical investigations of lung functions in vivo including plethysmography, bronchoalveolar lavage (BAL), cytology, histology, immunohistochemistry, and analysis of biochemical, immunological and molecular parameters. Disease models cover allergic asthma, chronic bronchitis, lung fibrosis, emphysema, ARDS, psoriasis, wound healing, atopic dermatitis, IBD, Pseudomonas aeruginosa and influenza A virus infection. Target users are pharma and biotech drug discovery teams.
- In Vitro Services Predictive ex vivo and in vitro assays providing primary cell assays, cytokine/chemokine profiling, flow cytometry, and pathway interrogation to support mechanism of action (MoA) and candidate ranking. Integrates high-content analysis and translational biomarker packages aligned with regulatory expectations. Target users are pharma and biotech drug discovery teams.
- Technology Platform Validated respiratory models combined with state-of-the-art analytics ensuring sensitivity to pharmacodynamic effects. Supports plethysmography, BAL, imaging, and immunoassays for preclinical studies. Target users are drug discovery teams requiring reproducible preclinical endpoints.
- Preclinical Equipments Portfolio Portfolio of preclinical research equipment supporting plethysmography, bronchoalveolar lavage (BAL), imaging, and immunoassays used in client preclinical studies.
- Preclinical CRO Services Overall contract research organization offering consulting, preclinical research and subcontracting services in immunology and inflammation with an emphasis on lung diseases, including protocol design, biostatistics, and reporting to accelerate go/no-go decisions for pharma and biotech clients.
Companies that use Artimmune
Customer profileSegments3 records
Ideal customer profiles3 records
Artimmune technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Artimmune partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Key-ObscoreArtimmune results from a partnership between Key-Obs and the laboratory of Immunology INEM - UMR7355 - CNRS. This partnership established relevant experimental models of lung diseases proposed in an expert environment for preclinical drug discovery.
- INEM - UMR7355 - CNRS (University of Orléans)corePartnership with the laboratory of Immunology INEM - UMR7355 - CNRS (CNRS and University of Orléans, France) has allowed establishment of relevant experimental models of lung diseases for preclinical research services.
- AFSSI Sciences de la VieminorArtimmune is a member of the French Association AFSSI Sciences de la Vie, a professional association for life sciences companies in France.
Scale indicators1 record
Recent moves4 records
Expansion highlights3 records
Artimmune competitors and assessment
Company assessmentDirect peers
- Key-Obs: Parent organization of Artimmune and a French preclinical CRO offering pharmacology and toxicology services. Highly comparable given shared ownership, overlapping services, and similar customer base in pharma and biotech.
- Scantox (formerly CiToxLAB): European preclinical CRO offering in vivo pharmacology and toxicology including respiratory and inflammation models. Comparable as a regional specialist CRO serving pharma and biotech preclinical programs.
- Porsolt: French preclinical CRO specializing in pharmacology studies including respiratory and inflammation models. Closest geographic and capability match to Artimmune as a similarly sized specialist serving pharma and biotech preclinical needs.
- Physiogenex: Preclinical CRO focused on metabolic disease and pharmacology models, including respiratory and inflammation studies. Comparable as a similarly sized specialist preclinical CRO competing for outsourced respiratory pharmacology work.
Broad incumbents
- Labcorp Drug Development (Covance): Large CRO offering preclinical research, biomarkers, and clinical development services. Overlaps with Artimmune in preclinical inflammation and respiratory pharmacology as part of a much broader portfolio.
- Inotiv: Contract research services provider with preclinical, toxicology, and research models capabilities. Comparable in offering outsourced preclinical services though operating at broader scale across multiple therapeutic areas.
- Charles River Laboratories: Global CRO with extensive preclinical research, discovery, and safety assessment services including respiratory disease models. A broad incumbent competing in many of the same therapeutic areas though at vastly larger scale.
- Eurofins Scientific: Large global CRO and life science testing platform with broad preclinical, immunology, and biomarker offerings. Overlaps with Artimmune through its preclinical discovery services but operates at substantially larger scale with broader portfolio.
Emerging players
- Reaction Biology Corporation: Preclinical CRO providing in vitro and in vivo services including inflammation and immune-related assays. Comparable as a growing specialty CRO with overlapping assay and disease-model capabilities in the same therapeutic area.
Others
- AFSSI Sciences de la Vie: French industry association representing life sciences service companies. Not a direct competitor but a relevant ecosystem peer as Artimmune is a member; useful comparability as a federation of similar French CROs and preclinical service providers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks4 records
Key highlights5 records
Customer concentration
Artimmune social profiles
Digital presenceArtimmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
Artimmune leadership team
Management profileNumber of profiles
Artimmune funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Artimmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Artimmune
What does Artimmune do?
Artimmune is a French contract research organization (CRO) that offers consulting, preclinical research, and subcontracting services in immunology and inflammation, with an emphasis on lung diseases. The company provides in vivo and in vitro preclinical studies, validated respiratory disease models, biomarker strategies, and analytical services to pharmaceutical and biotechnology clients advancing drug discovery programs.
Is Artimmune a public or private company?
Artimmune is a private company. It is classified as corporate owned and is currently operating.
When was Artimmune founded?
Artimmune was founded in 2009. It employs 1 to 10 people.
Where is Artimmune based?
Artimmune is headquartered in Orléans, France, in the Europe region.
How does Artimmune make money?
Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are consulting Services and subcontracting Services.
Who are Artimmune's main competitors?
Direct peers on record are Key-Obs, Scantox (formerly CiToxLAB), Porsolt and Physiogenex. Broad incumbents are Labcorp Drug Development (Covance), Inotiv, Charles River Laboratories and Eurofins Scientific. Reaction Biology Corporation is listed as an emerging player. AFSSI Sciences de la Vie is listed as an others.
Does Artimmune have an API?
No public API is recorded for Artimmune.
What industry is Artimmune in?
Artimmune's product category is Preclinical Contract Research. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.